Conditional gene targeting for cancer gene therapy

Advanced Drug Delivery Reviews

Volumn 53, Issue 2, 2001, Pages 135-154

  Haviv, Yosef S ^a   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cancer gene therapy; Gene expression; Regulatory elements

Indexed keywords

GENETIC ENGINEERING; MOLECULAR BIOLOGY; ONCOLOGY; TISSUE;

THERAPUTIC INDEX;

CONTROLLED DRUG DELIVERY;

ACTIN BINDING PROTEIN; ALPHA FETOPROTEIN; ALPHA LACTALBUMIN; AMYLASE; BETA INTERFERON; CARCINOEMBRYONIC ANTIGEN; CYCLOOXYGENASE 2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GASTRIN RELEASING PEPTIDE; HEAT SHOCK PROTEIN 70; HEXOKINASE; IMMUNOGLOBULIN HEAVY CHAIN; KALLIKREIN; L PLASTIN; MACROPHAGE ACTIVATING FACTOR; MONOPHENOL MONOOXYGENASE; MYC PROTEIN; OSTEOCALCIN; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; TELOMERASE; TRANSCRIPTION FACTOR AP 2; TUMOR PROMOTER; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASOPRESSIN;

BRAIN TUMOR; BREAST CARCINOMA; CANCER; CANCER CELL; ENDOCRINE TUMOR; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; HEMATOPOIETIC SYSTEM; HUMAN; LIVER CELL CARCINOMA; LUNG CARCINOMA; LYMPHOMA; MELANOMA; ONCOGENE NEU; OSTEOSARCOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TRANSGENE; VIRUS REPLICATION;

ANIMALS; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); VIRUS REPLICATION;

EID: 0035904982     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00225-3     Document Type: Review

References (154)

1. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
2. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
3. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene
4. Recent advances in cancer research: Drug targeting without the use of monoclonal antibodies
5. Targeting of adenoviral vectors through a bispecific single-chain antibody
6. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors
7. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting
8. Targeting retroviral integration
9. Pseudotyped retroviral vectors for studies of human gene therapy
10. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
11. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma
12. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
13. Progress in transcriptionally targeted and regulatable vectors for genetic therapy
14. Positive genetic selection for gene disruption in mammalian cells by homologous recombination
15. Tumor-specific gene expression
16. Gene therapy: Designer promoters for tumour targeting
17. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system
18. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells
19. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers
20. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells
21. Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery
22. Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat
23. Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk-1) promoter/enhancer sequences
24. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications
25. Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences
26. Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector
27. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis
28. Genomic analysis of metastasis reveals an essential role for RhoC
29. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer
30. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis
31. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein. TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms
32. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy
33. Endoglin expression as a measure of microvessel density in cervical cancer
34. Integrins and signal transduction pathways: The road taken
35. Thrombin receptor overexpression in malignant and physiological invasion processes
36. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts
37. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin
38. Liposomes modified with a synthetic Arg-Gly-Asp mimetic inhibit lung metastasis of B16BL6 melanoma cells
39. Ligand binding regulates the directed movement of beta1 integrins on fibroblasts
40. Tyrosine kinase activity, cytoskeletal organization, and motility in human vascular endothelial cells
41. Agonist-stimulated cytoskeletal reorganization and signal transduction at focal adhesions in vascular smooth muscle cells require c-Src
42. Growth inhibition of Ph+ progenitor cells from CML patients using the tyrosine kinase inhibitor CGP57148B
43. Differential effect on U937 cell differentiation by targeting transcriptional factors implicated in tissue- or stage-specific induced integrin expression
44. Hypoxia response elements
45. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells
46. Suppression of tumor growth through disruption of hypoxia-inducible transcription
47. DNA replication control through interaction of E2F-RB and the origin recognition complex
48. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
49. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector
50. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
51. Hexokinase type II: A novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells
52. Gene therapy for cancer using tumour-specific prodrug activation
53. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements
54. Molecular chemotherapy for breast cancer
55. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells
56. The clinical study on secretory leukoprotease inhibitor (SLPI) in sera of patients with various pulmonary diseases
57. Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells
58. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: Increase of cell-associated SLPI by neutrophil elastase
59. Strategy for achieving selective killing of carcinomas
60. Identification of the secretory leukocyte protease inhibitor (SLPI) as a target of IRF-1 regulation
61. Transcriptional expression of apoptosis suppression gene bcl-2 in non-small cell lung carcinoma
62. Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells
63. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene
64. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras
65. Negative regulation of bcl-2 expression by p53 in hematopoietic cells
66. Molecular targets for breast cancer therapy and prevention
67. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides
68. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide
69. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis
70. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: An in vitro study relevant to bone marrow purging
71. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase
72. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model
73. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide
74. Gene therapy of murine teratocarcinoma: Separate functions for insulin-like growth factors I and II in immunogenicity and differentiation
75. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy
76. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter
77. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer
78. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
79. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
80. Prostate-specific amplification of expanded polyglutamine expression: A novel approach for cancer gene therapy
81. In vitro and in vivo targeting of gene expression to melanoma cells
82. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth
83. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells
84. High level expression of tissue inhibitors of metalloproteinases-1,-2 and -3 in melanoma cells achieved by adenovirus mediated gene transfer
85. Inhibition of melanoma tumor growth in vivo by survivin targeting
86. Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter
87. Evaluation of relative promoter strength in primary hepatocytes using optimized lipofection
88. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy
89. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene
90. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy
91. Gene therapy for cancer using tumour-specific prodrug activation
92. Therapeutic strategies using c-erbB-2 promoter-controlled drug activation
93. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo
94. In vivo adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing pancreatic cancer
95. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice
96. Engineering tissue-specific expression of a recombinant adenovirus: Selective transgene transcription in the pancreas using the amylase promoter
97. Surfactant protein A-directed toxin gene kills lung cancer cells in vitro
98. Cis-active elements controlling lung cell-specific expression of human pulmonary surfactant protein B gene
99. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy
100. Adenovirus-mediated suicide gene transfer to small cell lung carcinoma using a tumor-specific promoter
101. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA
102. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers
103. Tumour-specific arginine vasopressin promoter activation in small cell lung cancer
104. E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small cell lung cancer
105. Expression of the diphtheria toxin A-chain coding sequence under the control of promoters and enhancers from immunoglobulin genes as a means of directing toxicity to B-lymphoid cells
106. Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector
107. Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy
108. Inverse targeting of retroviral vectors: Selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells
109. Transcriptional targeting of retroviral vectors to the erythroblastic progeny of transduced hematopoietic stem cells
110. Mammary gland-specific nuclear factor activity is positively regulated by lactogenic hormones and negatively by milk stasis
111. Factors controlling the expression of mouse mammary tumour virus
112. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression
113. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach
114. Noninvasive gene targeting to the brain
115. Efficient transfection of human interferon-beta gene to human glioma cells by means of cationic multilamellar liposomes coupled with a monoclonal antibody
116. Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor
117. Cell-type-specific and regulatable transgenesis in the adult brain: Adenovirus-encoded combined transcriptional targeting and inducible transgene expression
118. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models
119. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy
120. Bone tissue specific transcriptional control: Options for targeting gene therapy to the skeleton
121. Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries
122. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir
123. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft
124. Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo
125. Response of heat shock element within the human HSP70 promoter to mutated p53 genes
126. Targeting gene expression to tumor cells with loss of wild-type p53 function
127. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells
128. Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter
129. Heat-induced gene expression as a novel targeted cancer gene therapy strategy
130. Photodynamic therapy-mediated oxidative stress as a molecular switch for the temporal expression of genes ligated to the human heat shock promoter
131. Use of the glucose starvation-inducible glucose-regulated protein 78 promoter in suicide gene therapy of murine fibrosarcoma
132. Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors
133. Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1)
134. Inducible control of gene expression: Prospects for gene therapy
135. Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells
136. A regulatory network for the efficient control of transgene expression
137. A regulatory system for target gene expression
138. Ligand-dependent regulation of plasmid-based transgene expression in vivo
139. Adenovirus-mediated regulable target gene expression in vivo
140. p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells
141. Reovirus therapy of tumors with activated Ras pathway
142. Vesicular stomatitis virus (VSV) therapy of tumors
143. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity
144. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
145. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency
146. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy
147. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
148. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
149. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
150. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel
151. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
152. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors
153. Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector
154. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors